HEPT

Cat. No.: HY-10892: FAQs
Data Sheet Handling Instructions Technical Support

HEPT is a potent and selective anti-HIV-1 agent.

For research use only. We do not sell to patients.

HEPT Chemical Structure

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All HIV Isoform Specific Products:

View All Isoforms

HIV HIV-1 HIV-2

Biological Activity
Purity & Documentation
References
Customer Review

Description

HEPT is a potent and selective anti-HIV-1 agent^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	CC₅₀	> 1 μM Compound: HEPT	Concentration which reduces the cell viability by 50% (CEM-SS / MT-4) Concentration which reduces the cell viability by 50% (CEM-SS / MT-4)	[PMID: 9191961]
MT4	CC₅₀	> 200 μg/mL Compound: HEPT	Concentration required to reduce human MT-4 cell viability by 50%. Concentration required to reduce human MT-4 cell viability by 50%.	[PMID: 1495006]
MT4	CC₅₀	> 25 μg/mL Compound: HEPT	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22652226]
MT4	IC₅₀	> 405.38 μM Compound: HEPT	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 18692274]
MT4	IC₅₀	> 405.8 μM Compound: 1, HEPT	Antiviral activity against HIV2 ROD in MT4 cells after 4 days by MTT method Antiviral activity against HIV2 ROD in MT4 cells after 4 days by MTT method	[PMID: 17095124]
MT4	CC₅₀	> 500 μM Compound: 1	Concentration of compound required to reduce the viability of mock infected MT-4 cells against HIV-1 by 50% Concentration of compound required to reduce the viability of mock infected MT-4 cells against HIV-1 by 50%	[PMID: 2016729]
MT4	CC₅₀	> 500 μM Compound: HEPT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells (HIV-1 HTLV-IIIB strain) by 50% was determined on 4th day after virus infection. Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells (HIV-1 HTLV-IIIB strain) by 50% was determined on 4th day after virus infection.	[PMID: 1992136]
MT4	CC₅₀	≤ 399 μM Compound: HEPT	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 18692274]
MT4	EC₅₀	3.28 μM Compound: HEPT	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days	[PMID: 22652226]
MT4	CC₅₀	405 μM Compound: HEPT	Cytotoxicity against MT4 cells after 4 days by MTT method Cytotoxicity against MT4 cells after 4 days by MTT method	[PMID: 17381078]
MT4	CC₅₀	405 μM Compound: 1, HEPT	Cytotoxicity against MT4 cells after 4 days by MTT method Cytotoxicity against MT4 cells after 4 days by MTT method	[PMID: 17095124]
MT4	CC₅₀	405 μM Compound: HEPT	Cytotoxic concentration that reduces the MT-4 cell viability by 50% Cytotoxic concentration that reduces the MT-4 cell viability by 50%	[PMID: 15149669]
MT4	IC₅₀	5.06 μM Compound: HEPT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 18692274]
MT4	IC₅₀	5.06 μM Compound: HEPT	Antiviral activity against wild type HIV1 3B in MT4 cells after 4 days by MTT method Antiviral activity against wild type HIV1 3B in MT4 cells after 4 days by MTT method	[PMID: 17381078]
MT4	IC₅₀	5.06 μM Compound: 1, HEPT	Antiviral activity against HIV1 3B in MT4 cells after 4 days by MTT method Antiviral activity against HIV1 3B in MT4 cells after 4 days by MTT method	[PMID: 17095124]
MT4	IC₅₀	5.06 μM Compound: HEPT	Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells	[PMID: 15149669]
MT4	CC₅₀	740 μM Compound: 1	Cytotoxic concentration required to reduce viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce viability of mock-infected MT-4 cells by 50%	10.1016/S0960-894X(00)80042-6
MT4	CC₅₀	740 μM Compound: HEPT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 7636846]
MT4	CC₅₀	740 μM Compound: 5e	Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 2479745]
MT4	CC₅₀	740 μM Compound: HEPT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 1992136]
MT4	CC₅₀	740 μM Compound: HEPT	Concentration of compound required to reduce the viability of mock-infected HIV-2 (LAV-2ROD)/MT-4 cells by 50% Concentration of compound required to reduce the viability of mock-infected HIV-2 (LAV-2ROD)/MT-4 cells by 50%	[PMID: 1732552]
MT4	CC₅₀	743 μM Compound: HEPT	Concentration required to reduce the viability of mock-infected MT-4 cells by 50%. Concentration required to reduce the viability of mock-infected MT-4 cells by 50%.	[PMID: 1732552]

Molecular Weight

308.35

Formula

C₁₄H₁₆N₂O₄S

CAS No.

123027-56-5

SMILES

O=C1NC(C(C)=C(SC2=CC=CC=C2)N1COCCO)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Tanaka H, et al. A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). J Med Chem. 1991 Jan;34(1):349-57. [Content Brief]

HEPT Related Classifications

Infection

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

HEPT123027-56-5HIVHuman immunodeficiency virusanti-HIV-1 agentInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #